| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
Institut National de la Santé et de la Recherche Médical, U-515, Prolifération, Différenciation et Processus Tumoraux, Bâtiment Kourilsky, Hôpital St. Antoine (H.T., C.M., F.G., Y.L.B., M.L.), 75012 Paris, France; Commissariat Energie Atomique (CEA), Service de Pharmacologie et dImmunologie, CEA Saclay (C.C.), 91190 Gif-sur-Yvette, France; and Department of Hormonal Biology, St. Louis Hospital (P.B.), 75010 Paris, France
Address all correspondence and requests for reprints to: Dr. M. Laurent, INSERM, U-515, Prolifération, Différenciation et Processus Tumoraux, Bâtiment Kourilsky, Hôpital St. Antoine, 184 rue du Fbg St. Antoine, 75012 Paris, France. E-mail: laurent{at}st-antoine.inserm.fr.
Immunochromatography has shown that human NOV (NOVH), a member of the CCN (CTGF/CYR61/NOV) family, forms a physiological complex with fibulin-1 in blood. We developed an enzyme immunoassay specific for NOVH and showed for the first time that the concentration of NOVH differs in each of these biological fluids. The normal concentration of NOVH circulating in the blood is 350400 ng/ml, but this concentration varies with age. By using sera from patients with adrenal gland diseases we found that in vivo ACTH or glucocorticoids are not responsible for the high concentration of NOVH in this endocrine gland. However, the NOVH concentration was significantly modified in malignant adrenocortical tumors, but not in benign adrenocortical tumors. The concentration of NOVH was significantly decreased in patients suffering from astrocytomas or multiple sclerosis, two diseases of the nervous system. Thus, NOVH is a potentially useful marker for the diagnosis of these diseases.
Abbreviations: AchE, Acetylcholinesterase; CTGF, connective tissue growth factor; EIA, enzyme immunoassay; FCS, fetal calf serum; Ni-NTA, nickel nitrilotriacetic acid; NOVH, human NOV; PVDF, polyvinylidene difluoride; TCA, trichloroacetic acid.
This article has been cited by other articles:
![]() |
M. Doghman, M. Arhatte, H. Thibout, G. Rodrigues, J. De Moura, S. Grosso, A. N. West, M. Laurent, J.-C. Mas, A. Bongain, et al. Nephroblastoma Overexpressed/Cysteine-Rich Protein 61/Connective Tissue Growth Factor/Nephroblastoma Overexpressed Gene-3 (NOV/CCN3), a Selective Adrenocortical Cell Proapoptotic Factor, Is Down-Regulated in Childhood Adrenocortical Tumors J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3253 - 3260. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Gupta, D. Hong, F. Iborra, S. Sarno, and T. Enver NOV (CCN3) Functions as a Regulator of Human Hematopoietic Stem or Progenitor Cells Science, April 27, 2007; 316(5824): 590 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. T. Fu, J. F. Bechberger, M. A. Ozog, B. Perbal, and C. C. Naus CCN3 (NOV) Interacts with Connexin43 in C6 Glioma Cells: POSSIBLE MECHANISM OF CONNEXIN-MEDIATED GROWTH SUPPRESSION J. Biol. Chem., August 27, 2004; 279(35): 36943 - 36950. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |